Fungal infection of eye

Summary

Fungal infection of eye (MONDO:0020944) is a disease and 2 clinical trials. Top therapeutic interventions include voriconazole and natamycin. A subtype of fungal infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	fungal infection of eye
Mondo ID	MONDO:0020944
MeSH	D015821
SNOMED CT	31194008
UMLS	C0015405
MedGen	41935
Anatomy (UBERON)	UBERON:0000970
Is cancer (heuristic)	no

Also known as: EYE INFECT FUNGAL · Eye Infection, Fungal · Eye Infections, Fungal · FUNGAL EYE INFECT · Fungal Eye Infection · Fungal eye infection · Fungal Eye Infections · fungal infection of eye · Fungal Ocular Infection · Fungal Ocular Infections · Infection, Fungal Eye · Infection, Fungal Ocular · Infection, Ocular Mycotic · Infections, Fungal Eye · Infections, Fungal Ocular · Infections, Ocular Mycotic · Mycoses, Ocular · Mycosis, Ocular · MYCOTIC INFECT OCULAR · Mycotic Infection, Ocular (+11 more)

Disease family

This is a subtype of fungal infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › fungal infection of eye

Related subtypes (17): cutaneous mycosis, systemic mycosis, fungal esophagitis, opportunistic mycosis, fungal gastritis, fungal lung infectious disease, Pneumocystis infectious disease, sporotrichosis, fungal meningitis, fungal myositis, scedosporiosis, mycotic endocarditis, mycotoxicosis, alternariosis, invasive scopulariopsis infection, emergomycosis, fungal discitis

Subtypes (2): histoplasmosis retinitis, fungal keratitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00996736	PHASE3	COMPLETED	Mycotic Ulcer Treatment Trial I
NCT00997035	PHASE3	COMPLETED	The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VORICONAZOLE	4	2
NATAMYCIN	4	1
CHEMBL4740747	0	1